"Despite the potential benefits (fewer biopsies, less cost), the proposed approach to cancer detection and biopsy—that can miss 16%-40% of existing csPCa—may be difficult to justify for all patients," writes Badar M. Mian, MD.
Badar M. Mian, MD
Study findings bolster the idea that frequent repeat biopsies are unnecessary.
"This important study provides strong validation of the utility of multiparametric MRI of the prostate prior to initial biopsy," writes Badar M. Mian, MD.
"While improving local control seems to be important, especially in those with high-risk features, it’s not clear whether adjuvant EBRT is necessarily better than early salvage EBRT," writes Badar M. Mian, MD.
"The management of prostate cancer always requires caution to safeguard against avoidable risks from both the treatment and the monitoring protocol," writes Badar M. Mian, MD.
"In the end, it is up to the surgeons who wish to continue to perform these robotic procedure to demonstrate their cost-effectiveness," writes Badar M. Mian, MD.
Mitomycin C instillation within 24 hours after transurethral resection of non-muscle invasive bladder cancer significantly reduces the risk of recurrence and delays the time to recurrence.
Robot-assisted radical prostatectomy was associated with earlier and increased rate of recovery of erectile function when compared to radical retropubic prostatectomy and a slightly higher but acceptable rate of positive surgical margins, according to a study published online in European Urology (Sept. 4, 2017).
A recent review of two phase III randomized controlled trials demonstrated that addition of androgen deprivation therapy to salvage pelvic radiation therapy for prostate cancer recurrence after radical prostatectomy reduces the risk of metastases and improves overall survival.
In a recent study, increasing hospital volume was significantly associated with improved perioperative outcomes.